Nanobiotix (NASDAQ:NBTX) Stock Price Down 4.3% – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) shares fell 4.3% on Tuesday. The company traded as low as $32.47 and last traded at $31.8910. 2,874 shares were traded during trading, a decline of 97% from the average session volume of 88,874 shares. The stock had previously closed at $33.31.

Analyst Upgrades and Downgrades

NBTX has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. Guggenheim started coverage on Nanobiotix in a research report on Tuesday, September 15th. They set a “buy” rating and a $64.00 price target for the company. Finally, Leerink Partners upped their price objective on Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 4th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and an average target price of $46.67.

Nanobiotix Trading Down 3.2%

The business has a 50 day simple moving average of $38.67 and a two-hundred day simple moving average of $37.30.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.